This study is investigating a new way to manage chemotherapy-induced peripheral neuropathy (CIPN), which is nerve damage from chemotherapy. All participants will report their CIPN symptoms daily for 12 weeks using an app, website, or phone. In one group, you'll be encouraged to contact your own doctor for uncontrolled symptoms. In the other group, if your symptoms are concerning, a nurse practitioner will call you back the same or next day to suggest treatments. The study aims to see if this remote monitoring with nurse practitioner follow-up helps improve your symptoms. You may be eligible if you are 18 or older and have experienced CIPN after certain chemotherapy treatments like taxane, platinum, or bortezomib within the last 540 days, or are on ongoing maintenance therapy with some of these drugs. The study is currently unclear on its recruitment status and plans to enroll 422 participants.

Study design

This is a randomized controlled trial where participants are assigned to one of two groups by chance. It aims to enroll 422 participants, and the outcome assessor will not know which group you are in.

What's involved

You will report your CIPN symptoms daily for a one-week run-in period, and then for a 12-week study period using an app, website, or phone. If in the nurse practitioner group, you may receive phone calls for symptom management.

Compensation

Not stated in the trial record.

Follow-up

Your symptoms will be measured at the end of the 12-week study period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.